EHA 2024: Updates in the Treatment of CLL - Episode 16
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Video content above is prompted by the following:
- Briefly comment on the recent FDA accelerated approval granted to lisocabtagene maraleucel (liso-cel) based on the findings from TRANSCEND CLL 004.
- How may this impact future treatment practices? In which patients may you consider this treatment approach?
Related Content:
